文献速递重症综合管理与镇静镇痛

血管加压素与糖皮质激素治疗与脑死亡供者器官获取数量的关联:日本多中心队列研究

Associations of Vasopressin and Corticosteroid Therapy with Organ Yield in Brain-Dead Donors: A Multicenter Cohort Study in Japan.
PubMed 文献 · Neurocrit Care · 2026-09-17
一句话结论在日本16家机构脑死亡供者队列中,低剂量甲泼尼龙(<15 mg/kg/天)与更高器官获取数量相关(OR 2.86),而血管加压素剂量无此关联。

该多中心回顾性队列基于日本J-RESPECT队列,纳入2010年7月17日至2023年12月31日16家机构的脑死亡供者,按获取器官数中位数分为高产量组(≥6个器官)和低产量组(≤5个器官)。调整供者特征、合并儿茶酚胺支持及家属请求器官数后,低剂量甲泼尼龙(<15 mg/kg/天)与高产量器官获取的较高 odds 相关(OR 2.86,95%CI 1.45-5.63),而血管加压素剂量无此关联。探索性器官特异性分析中,高剂量甲泼尼龙(≥15 mg/kg/天)与左肺获取相关,其他器官未见一致关联。作者认为这些发现应谨慎解读,并需前瞻性研究确认。

要点

  • 低剂量甲泼尼龙(<15 mg/kg/天)与高产量器官获取(≥6个器官)的较高 odds 相关(OR 2.86,95%CI 1.45-5.63)。
  • 血管加压素剂量与高产量器官获取无关联。
  • 高剂量甲泼尼龙(≥15 mg/kg/天)在探索性分析中与左肺获取相关,其他器官未见一致关联。
  • 高产量组(n=125)获取器官中位数7个,低产量组(n=79)为4个。
  • 作者认为这些发现应谨慎解读,并需前瞻性研究确认。

适用人群与场景

  • 日本16家机构的脑死亡供者,数据来源于J-RESPECT队列,纳入时间为2010年7月17日至2023年12月31日。
  • 供者中位年龄47岁,92例(45.1%)为女性,入院至器官获取的中位时间为10天。

诊断标准与关键阈值

  • 按获取器官数中位数将供者分为高产量组(≥6个器官)和低产量组(≤5个器官)。

处置流程与药物剂量

  • 低剂量甲泼尼龙定义为<15 mg/kg/天;高剂量甲泼尼龙定义为≥15 mg/kg/天。
  • 血管加压素剂量按分类分析,原文未给出具体剂量分类阈值。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入日本16家机构脑死亡供者,高产量组n=125,低产量组n=79。
  • 高产量组获取器官中位数7个,低产量组为4个。
  • 调整供者特征、合并儿茶酚胺支持及家属请求器官数后,低剂量甲泼尼龙(<15 mg/kg/天)与高产量器官获取的较高 odds 相关(OR 2.86,95%CI 1.45-5.63)。
  • 血管加压素剂量与高产量器官获取无关联。
  • 探索性器官特异性分析中,高剂量甲泼尼龙(≥15 mg/kg/天)与左肺获取相关,其他器官未见一致关联。

证据类型、等级与局限

  • 多中心回顾性队列研究。
  • 局限:作者指出这些发现应谨慎解读,并需前瞻性研究确认。

对床旁实践的改变

  • 作者认为低剂量甲泼尼龙(<15 mg/kg/天)与更高器官获取数量相关,但强调应谨慎解读并需前瞻性研究确认。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Optimizing intensive care management of cases in which donors are brain-dead is essential to maximize the number of transplantable organs. Hormone replacement therapy, including vasopressin and corticosteroids, is widely used to stabilize donor hemodynamics; however, its impact on organ procurement remains uncertain. This study aimed to evaluate the association between vasopressin, corticosteroid therapy, and organ yield among donors who were brain-dead.

METHODS: We conducted a multicenter, retrospective analysis of the Japan Comprehensive Process for End-of-Life Care and Organ Donation after Brain Death (J-RESPECT) cohort, including data from 16 institutions in Japan between 17 July 2010 and 31 December 2023. Donors were classified into high-yield (≥ 6 organs) and low-yield (≤ 5 organs) groups based on the median number of organs procured. Vasopressin and corticosteroid doses were categorized, and generalized estimating equations were applied to assess associations with high-yield procurement and organ-specific donation, adjusting for donor characteristics and clinical variables.

RESULTS: The median donor age was 47 years, 92 donors (45.1%) were female, and the median time from admission to procurement was 10 days. Donors in the high-yield group (n = 125) had a median of seven organs procured compared with four in the low-yield group (n = 79). After adjustment for donor characteristics, concurrent catecholamine support, and the number of organs requested by the family, low-dose methylprednisolone (< 15 mg/kg/day) was associated with higher odds of high-yield organ procurement (odds ratios, 2.86; 95% confidence intervals, 1.45-5.63), whereas vasopressin dose was not. In exploratory organ-specific analyses, high-dose methylprednisolone (≥ 15 mg/kg/day) was associated with left lung procurement, whereas no consistent associations were observed for other organs.

CONCLUSIONS: In this multicenter cohort study, low-dose methylprednisolone, but not vasopressin dose, was associated with higher organ yield after adjustment for important clinical confounders. These findings should be interpreted cautiously and warrant confirmation in prospective studies to better define the role of individual hormone replacement therapies in donor case management.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Yumoto T, Naito H, Hongo T, et al. Associations of Vasopressin and Corticosteroid Therapy with Organ Yield in Brain-Dead Donors: A Multicenter Cohort Study in Japan. Neurocrit Care. 2026. PMID: 42754809. doi:10.1007/s12028-026-02645-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。